Main menu

Prediction of bladder cancer disease course
using risk scores that combine molecular and clinical risk factors

- a FP7 project partly financed by the European Commission, Feb 2008 - Sep 2013

 

top row from left: F. Real, Victor, W. Beukers, S. Tjin, E. Steyerberg, T.F. Ørntoft, L. Dyrskjøt, C.B. Pedersen, N. Malats
bottom row from left: E. Zwarthoff, F. Algaba, P.U. Malmström, U. Segersten, M.L. Calle

 

Background

Bladder cancer is a recurrent and very prevalent cancer in the EU. This cancer disease generates the highest cost per patient in Europe.
About one in 1500 people is under surveillance for possible bladder cancer recurrences.

 

Genomics

New genomic methods have allowed identifying new markers with potential clinical application.
Genetic mutations, expression profiles, and microsatellite alterations in tumor tissue and urine, as well as polymorphisms in immune response genes, are very promising biomarkers that predict a tumor being present in the bladder and its likelihood of progression to invade the muscle.

 

Uromol Project

In the UROMOL project we will combine the best markers for bladder cancer detection and outcome in a prospective multicenter validation study.

To achieve enough power to rapidly generate conclusive results, 2000 patients will consecutively be enrolled, and subjected to analysis.
The approach is a pre-defined, standard operating procedure based, prospective study with fixed end-points and testing relatively few independent variables on tumor tissue, urine and blood.
Successfully validated biomarkers will lead to specific recommendations for changes in patient management based on the risk scores.

We estimate saving of more than 40 mill Euros annually based on a reduced frequency of cystoscopies, as well as an increased survival and a better quality of life for the patients. The project will be carried out with the highest possible ethical standards, complying with all EU and national regulations.

 

 

Department of Molecular Medicine
Department of Clinical Biochemistry,
Aarhus University Hospital, Skejby,
Denmark

Department of Experimental and Healtth Sciences
Universitat Pompeu Fabra,
Barcelona,
Spain

Centro Nacional de Investigaciones Oncológicas
Madrid,
Spain

Department of Systems Biology
University of Vic, Vic,
Spain

Department of Pathology, Department of Urology & Department of Public Health
Erasmus MC,
University Medical Center Rotterdam,
The Netherlands

Department of Urology
University Hospital, Uppsala,
Sweden

Department of Urology
Fundació Puigvert, Barcelona,
Spain

 

Aarhus University Hospital, Skejby, Denmark

Prof. Torben Falck Ørntoft
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Assoc. prof. Lars Dyrskjøt Andersen
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Academic ass. manager Christina Bak Pedersen
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Universitat Pompeu Fabra, Barcelona, Spain

Prof. Francisco X. Real
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

Prof. Núria Malats
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Assoc. prof. Laia Palencia

Universidad de Vic, Vic, Spain

Prof. María-Luz Calle
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

PhD-student Núria Porta

Erasmus Medical Center, Rotterdam, The Netherlands

Prof: Ellen C. Zwarthoff
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Prof: Ewout Steyerberg
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Uppsala University Hospital

Prof. Per-Uno Malmström
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Post doc. Ulrika Segersten
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Fundació Puigvert, Barcelona, Spain

Assoc. prof. Ferran Algaba
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

The Commission of European Communities

EU-Project officer Alfredo Cesario
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Coordinator

Department of Molecular Medicine (MOMA)

Aarhus University Hospital, Skejby
Palle Juul-Jensens Boulevard 99
DK-8200 Aarhus N

telephone: (+45) 784 55310